Cost-effective, high-yield production system for human-like blood-clotting factors for haemophilia therapy
Date: 3.8.2015
| Summary: | |
| An Austrian university has developed a production system in fungi to produce an enzymatically active recombinant blood clotting factor. These factors can essentially reduce the risk of blood infections during haemophilia therapy. The world-wide new development enables a stable production of blood clotting factors, cheaper and higher yielding than human-based factor concentrates. They are looking for industrial partners for licence agreements, commercial and technical cooperation agreements. | |
| Reference: | TOAT20150529001 |
| Country: | Austria |
| Submitted: | May 29 2015 |
| Updated: | Jul 22 2015 |
| View Partnering Opportunity | |
| KEYWORDS | |
| Market: | Anatomy, Pathology, Immunology, Physiology , Other medical/health related (not elsewhere classified) , Other therapeutic (including defibrillators) |
| Technology: | Enzyme Technology, Microbiology , Pharmaceutical Products / Drugs |
| NACE: | Post-secondary non-tertiary education, Tertiary education |
